

CITATION REPORT

List of articles citing

An automated database case definition for serious bleeding related to oral anticoagulant use

DOI: 10.1002/pds.2109

Pharmacoepidemiology and Drug Safety, 2011, 20, 560-6.

Source: <https://exaly.com/paper-pdf/51451674/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
261	Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. 2012 , 126, 1185-93		317
260	Improving sensitivity of machine learning methods for automated case identification from free-text electronic medical records. 2013 , 13, 30		24
259	Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. 2013 , 62, 981-9		265
258	Automating case definitions using literature-based reasoning. 2013 , 4, 515-27		8
257	Genotype and risk of major bleeding during warfarin treatment. 2014 , 15, 1973-83		45
256	Characteristics of patients with non-valvular atrial fibrillation using dabigatran or warfarin in the US. <i>Current Medical Research and Opinion</i> , 2014 , 30, 795-804	2.5	13
255	Genetic risk factors for major bleeding in patients treated with warfarin in a community setting. <i>Clinical Pharmacology and Therapeutics</i> , 2014 , 95, 636-43	6.1	30
254	Serious bleeding events due to warfarin and antibiotic co-prescription in a cohort of veterans. 2014 , 127, 657-663.e2		41
253	Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study. 2014 , 129, 1577-85		204
252	Clopidogrel bioactivation and risk of bleeding in patients cotreated with angiotensin-converting enzyme inhibitors after myocardial infarction: a proof-of-concept study. <i>Clinical Pharmacology and Therapeutics</i> , 2014 , 96, 713-22	6.1	20
251	Intracranial hemorrhage mortality in atrial fibrillation patients treated with dabigatran or warfarin. 2014 , 45, 2286-91		56
250	Characterizing major bleeding in patients with nonvalvular atrial fibrillation: a pharmacovigilance study of 27 467 patients taking rivaroxaban. 2015 , 38, 63-8		122
249	Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2015 , 114, 1277-89	7	97
248	Predictors of gastrointestinal bleeding among patients with atrial fibrillation after initiating dabigatran therapy. 2015 , 35, 560-8		27
247	Stroke and recurrent haemorrhage associated with antithrombotic treatment after gastrointestinal bleeding in patients with atrial fibrillation: nationwide cohort study. 2015 , 351, h5876		91
246	Oral anticoagulation therapy after radiofrequency ablation of atrial fibrillation and the risk of thromboembolism and serious bleeding: long-term follow-up in nationwide cohort of Denmark. 2015 , 36, 307-14a		70
245	Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. 2015 , 131, 157-64		500

244	Usefulness of Health Registers for detection of bleeding events in outcome studies. <i>Thrombosis and Haemostasis</i> , 2016 , 116, 1131-1139	7	25
243	Comparative evaluation of methods approximating drug prescription durations in claims data: modeling, simulation, and application to real data. <i>Pharmacoepidemiology and Drug Safety</i> , 2016 , 25, 1434-1442	2.6	10
242	Substantial differences in initiation of oral anticoagulant therapy and clinical outcome among non-valvular atrial fibrillation patients treated in inpatient and outpatient settings. 2016 , 18, 492-500		11
241	Outcomes associated with observation status versus inpatient management of pulmonary embolism patients anticoagulated with rivaroxaban. 2016 , 222, 846-849		1
240	Risk Factors for Major Bleeding in Rivaroxaban Users With Atrial Fibrillation. 2016 , 68, 1144-6		4
239	Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a "real-world" observational study in the United States. 2016 , 70, 752-63		85
238	Association of Proton Pump Inhibitors With Reduced Risk of Warfarin-Related Serious Upper Gastrointestinal Bleeding. 2016 , 151, 1105-1112.e10		48
237	Outcomes associated with observation stays versus inpatient admissions for pulmonary embolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2016 , 42, 513-9	5.1	3
236	Rivaroxaban real-world evidence: Validating safety and effectiveness in clinical practice. <i>Thrombosis and Haemostasis</i> , 2016 , 116, S13-S23	7	31
235	Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis. <i>Thrombosis and Haemostasis</i> , 2016 , 116, 975-986	7	190
234	Outcomes related to variation in hospital pulmonary embolus observation stay utilization. 2016 , 44, 133-7		1
233	Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2016 , 5,	6	261
232	Assessing generalizability of trial results in general practice. 2016 , 37, 1154-7		8
231	An early evaluation of bleeding-related hospital readmissions among hospitalized patients with nonvalvular atrial fibrillation treated with direct oral anticoagulants. <i>Current Medical Research and Opinion</i> , 2016 , 32, 573-82	2.5	35
230	Evaluation of the F2R IVS-14A/T PAR1 polymorphism with subsequent cardiovascular events and bleeding in patients who have undergone percutaneous coronary intervention. <i>Journal of Thrombosis and Thrombolysis</i> , 2016 , 41, 656-62	5.1	7
229	Shortened hospital length of stay and lower costs associated with rivaroxaban in patients with pulmonary embolism managed as observation status. 2017 , 71, e12915		2
228	Treatment of atrial fibrillation with warfarin among older adults with end stage renal disease. 2017 , 30, 831-839		5
227	Major Bleeding Complications and Persistence With Oral Anticoagulation in Non-Valvular Atrial Fibrillation: Contemporary Findings in Real-Life Danish Patients. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	74

226	Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population. <i>Current Medical Research and Opinion</i> , 2017 , 33, 1595-1604	2.5	42
225	Impact of renal function on ischemic stroke and major bleeding rates in nonvalvular atrial fibrillation patients treated with warfarin or rivaroxaban: a retrospective cohort study using real-world evidence. <i>Current Medical Research and Opinion</i> , 2017 , 33, 1891-1900	2.5	17
224	Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients. <i>Current Medical Research and Opinion</i> , 2017 , 33, 1745-1754	2.5	52
223	Propensity Score Weighting Compared to Matching in a Study of Dabigatran and Warfarin. 2017 , 40, 169-181		12
222	CHADS-VASc Scores and Major Bleeding in Patients With Nonvalvular Atrial Fibrillation Who Are Receiving Rivaroxaban. 2017 , 69, 541-550.e1		9
221	Stroke risk reduction outweighed bleeding risk increase from vitamin K antagonist treatment among nonvalvular atrial fibrillation patients with high stroke risk and low bleeding risk. <i>Current Medical Research and Opinion</i> , 2017 , 33, 631-638	2.5	
220	Comparison of the Incidence of Major Bleeding With Rivaroxaban Use Among Nonvalvular Atrial Fibrillation Patients With Versus Without Diabetes Mellitus. 2017 , 119, 753-759		11
219	Effectiveness and safety of oral anticoagulation with non-vitamin K antagonists compared to well-managed vitamin K antagonists in naïve patients with non-valvular atrial fibrillation: Propensity score matched cohort study. 2017 , 249, 198-203		20
218	Long-term stroke and bleeding risk in patients with atrial fibrillation treated with oral anticoagulants in contemporary practice: Providing evidence for shared decision-making. 2017 , 245, 174-177		7
217	A post-marketing assessment of major bleeding in total hip and total knee replacement surgery patients receiving rivaroxaban. <i>Current Medical Research and Opinion</i> , 2017 , 33, 1717-1723	2.5	3
216	Risk for Venous Thromboembolism Recurrence Among Rivaroxaban-treated Patients Who Continued Versus Discontinued Therapy: Analyses Among Patients with VTE. <i>Clinical Therapeutics</i> , 2017 , 39, 1396-1408	3.5	6
215	Hospital length-of-stay and costs among pulmonary embolism patients treated with rivaroxaban versus parenteral bridging to warfarin. 2017 , 12, 311-318		11
214	The Role of Hemoglobin Laboratory Test Results for the Detection of Upper Gastrointestinal Bleeding Outcomes Resulting from the Use of Medications in Observational Studies. 2017 , 40, 91-100		
213	Comparative effectiveness of dabigatran and rivaroxaban versus warfarin for the treatment of non-valvular atrial fibrillation. 2017 , 69, 868-876		43
212	Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 1841-1847	7	25
211	Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in "real-world" clinical practice. A propensity-matched analysis of 76,940 patients. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 1072-1082	7	102
210	Comparative safety and effectiveness of rivaroxaban versus VKAs in patients with venous thromboembolism. A Danish nationwide registry-based study. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 1182-1191	7	29
209	Major Bleeding Risk During Anticoagulation with Warfarin, Dabigatran, Apixaban, or Rivaroxaban in Patients with Nonvalvular Atrial Fibrillation. 2017 , 23, 968-978		70

208	Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation. <i>BMC Cardiovascular Disorders</i> , 2017 , 17, 238	2.3	40
207	Risk of cardiovascular events and incident atrial fibrillation in patients without prior atrial fibrillation: Implications for expanding the indications for anticoagulation. <i>American Heart Journal</i> , 2018 , 199, 137-143	4.9	3
206	Effectiveness and safety of rivaroxaban vs warfarin in people with non-valvular atrial fibrillation and diabetes: an administrative claims database analysis. 2018 , 35, 1105-1110		21
205	Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2018 , 7,	6	56
204	Rationale, design, and preliminary results of the Quebec Warfarin Cohort Study. 2018 , 41, 576-585		10
203	Effectiveness and safety of anticoagulants for the treatment of venous thromboembolism in patients with cancer. <i>American Journal of Hematology</i> , 2018 , 93, 664-671	7.1	54
202	Effectiveness and safety of outpatient rivaroxaban versus warfarin for treatment of venous thromboembolism in patients with a known primary hypercoagulable state. <i>Thrombosis Research</i> , 2018 , 163, 132-137	8.2	5
201	Prospective surveillance pilot of rivaroxaban safety within the US Food and Drug Administration Sentinel System. <i>Pharmacoepidemiology and Drug Safety</i> , 2018 , 27, 263-271	2.6	14
200	Effectiveness and safety of rivaroxaban vs. warfarin in patients 80+ years of age with non-valvular atrial fibrillation. 2018 , 4, 328-329		8
199	Outcomes of Patients With Atrial Fibrillation Newly Recommended for Oral Anticoagulation Under the 2014 American Heart Association/American College of Cardiology/Heart Rhythm Society Guideline. <i>Journal of the American Heart Association</i> , 2018 , 7,	6	4
198	Agreement between coding schemas used to identify bleeding-related hospitalizations in claims analyses of nonvalvular atrial fibrillation patients. 2018 , 41, 119-125		3
197	Different safety profiles of oral anticoagulants in very elderly non-valvular atrial fibrillation patients. A retrospective propensity score matched cohort study. 2018 , 265, 103-107		14
196	Systematic Review and Meta-Analysis of Real-World Studies Evaluating Rivaroxaban for Cancer-Associated Venous Thrombosis. 2018 , 38, 610-618		6
195	Provider Specialty, Anticoagulation Prescription Patterns, and Stroke Risk in Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2018 , 7,	6	21
194	Effectiveness and Safety of Rivaroxaban Versus Warfarin in Frail Patients with Venous Thromboembolism. 2018 , 131, 933-938.e1		13
193	Real-world comparison of all-cause hospitalizations, hospitalizations due to stroke and major bleeding, and costs for non-valvular atrial fibrillation patients prescribed oral anticoagulants in a US health plan. 2018 , 21, 244-253		12
192	Outcomes associated with warfarin time in therapeutic range among US veterans with nonvalvular atrial fibrillation. <i>Current Medical Research and Opinion</i> , 2018 , 34, 415-421	2.5	13
191	Identifying Patients With High Data Completeness to Improve Validity of Comparative Effectiveness Research in Electronic Health Records Data. <i>Clinical Pharmacology and Therapeutics</i> , 2018 , 103, 899-905	6.1	19

190	Standard and reduced doses of dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study. 2018 , 283, 45-55		61
189	Safety assessment of niacin in the US Food and Drug Administration@ mini-sentinel system. <i>Pharmacoepidemiology and Drug Safety</i> , 2018 , 27, 30-37	2.6	10
188	Clinical outcomes of prolonged anticoagulation with rivaroxaban after unprovoked venous thromboembolism. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018 , 2, 58-68	5.1	5
187	Dabigatran Versus Rivaroxaban for Secondary Stroke Prevention in Patients with Atrial Fibrillation Rehabilitated in Skilled Nursing Facilities. 2018 , 35, 1089-1098		2
186	Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients. 2018 , 49, 2933-2944		157
185	Association of Oral Anticoagulants and Proton Pump Inhibitor Cotherapy With Hospitalization for Upper Gastrointestinal Tract Bleeding. <i>JAMA - Journal of the American Medical Association</i> , 2018 , 320, 2221-2230	27.4	80
184	Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation. 2018 , 2, 200-209		85
183	Impact of anticoagulant choice on hospitalized bleeding risk when treating cancer-associated venous thromboembolism. 2018 , 16, 2403-2412		15
182	Combining Oral Anticoagulants With Platelet Inhibitors in Patients With Atrial Fibrillation and Coronary Disease. 2018 , 72, 1790-1800		30
181	Effectiveness and Safety of Apixaban versus Warfarin as Outpatient Treatment of Venous Thromboembolism in U.S. Clinical Practice. <i>Thrombosis and Haemostasis</i> , 2018 , 118, 1951-1961	7	23
180	Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban. <i>PLoS ONE</i> , 2018 , 13, e0205989	3.7	34
179	Comparative effectiveness and safety of antiplatelet drugs in patients with diabetes mellitus and acute coronary syndrome. <i>Pharmacoepidemiology and Drug Safety</i> , 2018 , 27, 1361-1370	2.6	7
178	Real-World Comparative Effectiveness, Safety, and Health Care Costs of Oral Anticoagulants in Nonvalvular Atrial Fibrillation Patients in the U.S. Department of Defense Population. 2018 , 24, 1116-1127		22
177	A new model to predict major bleeding in patients with atrial fibrillation using warfarin or direct oral anticoagulants. <i>PLoS ONE</i> , 2018 , 13, e0203599	3.7	10
176	A Real-World Observational Study of Hospitalization and Health Care Costs Among Nonvalvular Atrial Fibrillation Patients Prescribed Oral Anticoagulants in the U.S. Medicare Population. 2018 , 24, 911-920		15
175	Effectiveness and Safety of Anticoagulants in Adults with Non-valvular Atrial Fibrillation and Concomitant Coronary/Peripheral Artery Disease. 2018 , 131, 1075-1085.e4		12
174	Safety and effectiveness of rivaroxaban and apixaban in patients with venous thromboembolism: a nationwide study. 2018 , 4, 220-227		10
173	Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States. 2018 , 138, 1519-1529		225

172	Defining Exposure in Observational Studies Comparing Outcomes of Treatment Discontinuation. 2018 , 11, e004684		3
171	Influence of Sociodemographic Factors and Provider Specialty on Anticoagulation Prescription Fill Patterns and Outcomes in Atrial Fibrillation. 2018 , 122, 388-394		4
170	Risks and Benefits of Direct Oral Anticoagulants across the Spectrum of GFR among Incident and Prevalent Patients with Atrial Fibrillation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018 , 13, 1144-1152	6.9	29
169	Out-of-system Care and Recording of Patient Characteristics Critical for Comparative Effectiveness Research. 2018 , 29, 356-363		13
168	Effectiveness and safety of rivaroxaban versus warfarin in patients with unprovoked venous thromboembolism: A propensity-score weighted administrative claims cohort study. <i>Thrombosis Research</i> , 2018 , 168, 31-36	8.2	8
167	Target Population of Non-deferrable Surgery and Uncontrolled Severe Bleeding Related to Dabigatran. 2018 , 32, 281-286		6
166	Effectiveness and safety of rivaroxaban versus warfarin in patients with provoked venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2018 , 46, 339-345	5.1	10
165	Length of hospitalization and mortality for bleeding during treatment with warfarin, dabigatran, or rivaroxaban. <i>PLoS ONE</i> , 2018 , 13, e0193912	3.7	5
164	Effectiveness and safety of rivaroxaban vs. warfarin in non-valvular atrial fibrillation patients with a non-sex-related CHA2DS2-VASc score of 1. 2019 , 5, 64-69		13
163	Safety, effectiveness, and health care cost comparisons among elderly patients with venous thromboembolism prescribed warfarin or apixaban in the United States Medicare population. <i>Current Medical Research and Opinion</i> , 2019 , 35, 2043-2051	2.5	8
162	Rivaroxaban® Impact on Renal Decline in Patients With Nonvalvular Atrial Fibrillation: A US MarketScan Claims Database Analysis. 2019 , 25, 1076029619868535		20
161	Comparative Effectiveness and Safety of Ticagrelor versus Prasugrel in Patients with Acute Coronary Syndrome: A Retrospective Cohort Analysis. 2019 , 39, 912-920		6
160	Discretionary Thrombophilia Test Acquisition and Outcomes in Patients With Venous Thromboembolism in a Real-World Clinical Setting. <i>Journal of the American Heart Association</i> , 2019 , 8, e013395	6	2
159	Non-vitamin K antagonist oral anticoagulants vs. vitamin-K antagonists in patients with atrial fibrillation and chronic kidney disease: a nationwide cohort study. 2019 , 17, 21		5
158	Rivaroxaban versus warfarin treatment among morbidly obese patients with venous thromboembolism: Comparative effectiveness, safety, and costs. <i>Thrombosis Research</i> , 2019 , 182, 159-166	8.2	29
157	A Case-Crossover-Based Screening Approach to Identifying Clinically Relevant Drug-Drug Interactions in Electronic Healthcare Data. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 106, 238-244	6.1	11
156	Comparison of real-world outcomes in patients with nonvalvular atrial fibrillation treated with direct oral anticoagulant agents or warfarin. 2019 , 76, 275-285		10
155	Evaluation of the US Food and Drug Administration Sentinel Analysis Tools Using a Comparator with a Different Indication: Comparing the Rates of Gastrointestinal Bleeding in Warfarin and Statin Users. 2019 , 33, 29-43		4

154	Effectiveness and safety of direct oral anticoagulants compared to warfarin in treatment naïve non-valvular atrial fibrillation patients in the US Department of defense population. <i>BMC Cardiovascular Disorders</i> , 2019 , 19, 142	2.3	8
153	Assessment of ICD-10-CM code assignment validity for case finding of outpatient anticoagulant-related bleeding among Medicare beneficiaries. <i>Pharmacoepidemiology and Drug Safety</i> , 2019 , 28, 951-964	2.6	6
152	Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Severe Kidney Disease or Undergoing Hemodialysis. 2019 , 132, 1078-1083		60
151	Comparisons between Oral Anticoagulants among Older Nonvalvular Atrial Fibrillation Patients. 2019 , 67, 1662-1671		25
150	Effectiveness and safety of rivaroxaban and warfarin for prevention of major adverse cardiovascular or limb events in patients with non-valvular atrial fibrillation and type 2 diabetes. 2019 , 21, 2107-2114		21
149	Bleeding incidence and risk factors among cancer patients treated with anticoagulation. <i>American Journal of Hematology</i> , 2019 , 94, 780-785	7.1	29
148	Changes in Anticoagulant Utilization Among United States Nursing Home Residents With Atrial Fibrillation From 2011 to 2016. <i>Journal of the American Heart Association</i> , 2019 , 8, e012023	6	33
147	Effectiveness and safety of oral anticoagulants in older adults with non-valvular atrial fibrillation and heart failure. <i>PLoS ONE</i> , 2019 , 14, e0213614	3.7	18
146	Risk of hospitalised bleeding in comparisons of oral anticoagulant options for the primary treatment of venous thromboembolism. 2019 , 185, 903-911		17
145	Incidence and Cost of Major Adverse Cardiovascular Events and Major Adverse Limb Events in Patients With Chronic Coronary Artery Disease or Peripheral Artery Disease. 2019 , 123, 1893-1899		15
144	Effects of body mass index on the safety and effectiveness of direct oral anticoagulants: a retrospective review. <i>Journal of Thrombosis and Thrombolysis</i> , 2019 , 48, 359-365	5.1	19
143	Comparative clinical outcomes between direct oral anticoagulants and warfarin among elderly patients with non-valvular atrial fibrillation in the CMS medicare population. <i>Journal of Thrombosis and Thrombolysis</i> , 2019 , 48, 240-249	5.1	8
142	Healthcare costs of stroke and major bleeding in patients with atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants. 2019 , 22, 751-759		5
141	Sequential Monitoring of the Comparative Effectiveness and Safety of Dabigatran in Routine Care. 2019 , 12, e005173		7
140	Duration of anticoagulant therapy and VTE recurrence in patients with cancer. 2019 , 27, 3833-3840		5
139	The value of sPESI for risk stratification in patients with pulmonary embolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2019 , 48, 149-157	5.1	9
138	Comparative effectiveness, safety, and costs of rivaroxaban and warfarin among morbidly obese patients with atrial fibrillation. <i>American Heart Journal</i> , 2019 , 212, 113-119	4.9	45
137	Validation of diagnostic codes of major clinical outcomes in a National Health Insurance database. 2019 , 20,		24

136	Bleeding in cardiac patients prescribed antithrombotic drugs: electronic health record phenotyping algorithms, incidence, trends and prognosis. 2019 , 17, 206		4
135	BenefitRisk Assessments of Medical Treatments. 2019 , 867-896		1
134	Sensitivity and specificity of an algorithm based on medico-administrative data to identify hospitalized patients with major bleeding presenting to an emergency department. 2019 , 19, 194		8
133	Impact of Prolonged Anticoagulation with Rivaroxaban on Provoked Venous Thromboembolism Recurrence: IMPROVE-VTE. 2019 , 132, 498-504		3
132	A new model to predict ischemic stroke in patients with atrial fibrillation using warfarin or direct oral anticoagulants. 2019 , 16, 820-826		3
131	Influence of Polypharmacy on the Effectiveness and Safety of Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation. 2019 , 39, 196-203		11
130	The risk of recurrent VTE and major bleeding in a commercially-insured population of cancer patients treated with anticoagulation. <i>American Journal of Hematology</i> , 2019 , 94, E58-E61	7.1	8
129	Developing a Conversation Aid to Support Shared Decision Making: Reflections on Designing Anticoagulation Choice. 2019 , 94, 686-696		20
128	Comparative Stroke, Bleeding, and Mortality Risks in Older Medicare Patients Treated with Oral Anticoagulants for Nonvalvular Atrial Fibrillation. 2019 , 132, 596-604.e11		73
127	Oral anticoagulation therapy and subsequent risk of venous thromboembolism in atrial fibrillation patients. <i>Current Medical Research and Opinion</i> , 2019 , 35, 837-845	2.5	10
126	Comparative risk of major bleeding with rivaroxaban and warfarin: Population-based cohort study of unprovoked venous thromboembolism. 2019 , 102, 143-149		3
125	Risk of Systemic Adverse Events Associated with Intravitreal Anti-VEGF Therapy for Diabetic Macular Edema in Routine Clinical Practice. 2019 , 126, 1007-1015		16
124	Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and heart failure. 2019 , 6, 10-15		5
123	Modeling the impact of real-world adherence to once-daily (QD) versus twice-daily (BID) non-vitamin K antagonist oral anticoagulants on stroke and major bleeding events among non-valvular atrial fibrillation patients. <i>Current Medical Research and Opinion</i> , 2019 , 35, 653-660	2.5	6
122	Warfarin use and the risk of stroke, bleeding, and mortality in older adults on dialysis with incident atrial fibrillation. 2019 , 24, 234-244		14
121	Real World Outcomes Associated with Idarucizumab: Population-Based Retrospective Cohort Study. <i>American Journal of Cardiovascular Drugs</i> , 2020 , 20, 161-168	4	12
120	Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and coronary or peripheral artery disease. 2020 , 6, 159-166		13
119	Rivaroxaban versus apixaban in non-valvular atrial fibrillation patients with end-stage renal disease or receiving dialysis. 2020 , 104, 328-335		17

118	Safety and Effectiveness of Dabigatran and Other Direct Oral Anticoagulants Compared With Warfarin in Patients With Atrial Fibrillation. <i>Clinical Pharmacology and Therapeutics</i> , 2020 , 107, 1405-1419 ^{6.1}	7
117	Association of Anticoagulant Therapy With Risk of Fracture Among Patients With Atrial Fibrillation. 2020 , 180, 245-253	30
116	Risk of gastrointestinal bleeding associated with oral anticoagulation and non-steroidal anti-inflammatory drugs in patients with atrial fibrillation: a nationwide study. 2020 , 6, 292-300	11
115	Rivaroxaban Versus Warfarin for Management of Obese African Americans With Non-Valvular Atrial Fibrillation or Venous Thromboembolism: A Retrospective Cohort Analysis. 2020 , 26, 1076029620954910	1
114	Risk of Ischemic Stroke in Patients With Atrial Fibrillation After Extracranial Hemorrhage. 2020 , 51, 3592-3599	1
113	Effectiveness and safety of oral anticoagulants among non-valvular atrial fibrillation patients with polypharmacy. 2021 , 7, 405-414	1
112	Rivaroxaban Versus Warfarin in African American Patients with Nonvalvular Atrial Fibrillation. 2020 , 112, 395-401	1
111	Impact of oral anticoagulation choice on healthcare utilization for the primary treatment of venous thromboembolism. 2020 , 25, 549-556	0
110	Impact of Hospitalization and Medication Switching on Post-discharge Adherence to Oral Anticoagulants in Patients With Atrial Fibrillation. 2020 , 40, 1022-1035	1
109	Burden-of-Illness Associated with Bleeding-Related Hospitalizations in Atrial Fibrillation Patients: Findings from the Nationwide Readmission Database. 2020 , 4, e211-e217	1
108	Effectiveness and safety of rivaroxaban compared with low-molecular-weight heparin in cancer-associated thromboembolism. 2020 , 4, 4045-4051	0
107	Effectiveness and Safety of Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation and Diabetes Mellitus. 2020 , 95, 929-943	12
106	Rivaroxaban Versus Apixaban for Stroke Prevention in Atrial Fibrillation: An Instrumental Variable Analysis of a Nationwide Cohort. 2020 , 13, e006058	10
105	Long-Term Cognitive Impairment Associated With Delirium in Acute Neurological Injury. 2020 , 2, e0130	3
104	Effectiveness and Safety of Oral Anticoagulants among NVAf Patients with Obesity: Insights from the ARISTOPHANES Study. 2020 , 9,	12
103	Direct-Acting Oral Anticoagulants Versus Warfarin in Medicare Patients With Chronic Kidney Disease and Atrial Fibrillation. 2020 , 51, 2364-2373	14
102	External Validation of an Algorithm to Identify Patients with High Data-Completeness in Electronic Health Records for Comparative Effectiveness Research. 2020 , 12, 133-141	6
101	Effectiveness and Safety of Direct Oral Anticoagulants versus Warfarin in Obese Patients with Acute Venous Thromboembolism. 2020 , 40, 204-210	31

100	Comparative effectiveness and safety of apixaban versus warfarin in patients with venous thromboembolism. 2020 , 77, 188-195		8
99	Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and stage IV-V chronic kidney disease. <i>American Heart Journal</i> , 2020 , 223, 3-11	4.9	20
98	Effectiveness and safety of rivaroxaban versus warfarin in obese nonvalvular atrial fibrillation patients: analysis of electronic health record data. <i>Current Medical Research and Opinion</i> , 2020 , 36, 1081-1088	3.5	19
97	A Real-World Observational Study of Hospitalization and Health Care Costs Among Nonvalvular Atrial Fibrillation Patients Prescribed Oral Anticoagulants in the U.S. Medicare Population. 2020 , 26, 639-651		1
96	Meta-Analysis Comparing Direct Oral Anticoagulants Versus Warfarin in Morbidly Obese Patients With Atrial Fibrillation. 2020 , 126, 23-28		16
95	Association of Oral Anticoagulants and Verapamil or Diltiazem With Adverse Bleeding Events in Patients With Nonvalvular Atrial Fibrillation and Normal Kidney Function. 2020 , 3, e203593		16
94	Association of Primary Intracerebral Hemorrhage With Pregnancy and the Postpartum Period. 2020 , 3, e202769		14
93	Comparative Safety and Effectiveness of Direct-Acting Oral Anticoagulants Versus Warfarin: a National Cohort Study of Nursing Home Residents. <i>Journal of General Internal Medicine</i> , 2020 , 35, 2329-2337	4	6
92	Rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism in African American patients: a retrospective cohort analysis. 2020 , 18, 6		2
91	Bleeding and recurrent VTE with apixaban vs warfarin as outpatient treatment: time-course and subgroup analyses. 2020 , 4, 432-439		5
90	Oral anticoagulants for nonvalvular atrial fibrillation in frail elderly patients: insights from the ARISTOPHANES study. 2021 , 289, 42-52		14
89	Effectiveness and safety of rivaroxaban versus warfarin in obese patients with acute venous thromboembolism: analysis of electronic health record data. <i>Journal of Thrombosis and Thrombolysis</i> , 2021 , 51, 349-358	5.1	8
88	All-cause mortality, stroke, and bleeding in patients with atrial fibrillation and valvular heart disease. 2021 , 7, f93-f100		9
87	Risk of Systemic Adverse Events after Intravitreal Bevacizumab, Ranibizumab, and Aflibercept in Routine Clinical Practice. 2021 , 128, 417-424		13
86	Safety and effectiveness of apixaban compared with warfarin among clinically-relevant subgroups of venous thromboembolism patients in the United States Medicare population. <i>Thrombosis Research</i> , 2021 , 198, 163-170	8.2	1
85	Effectiveness and Safety of Apixaban, Low-Molecular-Weight Heparin, and Warfarin among Venous Thromboembolism Patients with Active Cancer: A U.S. Claims Data Analysis. <i>Thrombosis and Haemostasis</i> , 2021 , 121, 383-395	7	9
84	Comparative effectiveness and safety of non-vitamin-K antagonist oral anticoagulants and warfarin in older adults with atrial fibrillation and diabetes. <i>Current Medical Research and Opinion</i> , 2021 , 37, 343-358	2.5	1
83	Vitamin K antagonists vs. direct oral anticoagulants after transcatheter aortic valve implantation in atrial fibrillation. 2021 , 7, 11-19		15

82	Geographic Variation in Anticoagulant Use and Resident, Nursing Home, and County Characteristics Associated With Treatment Among US Nursing Home Residents. 2021 , 22, 164-172.e9		0
81	Thromboembolism, bleeding and vascular death in nonvalvular atrial fibrillation patients with type 2 diabetes receiving rivaroxaban or warfarin. 2021 , 20, 52		4
80	A claims-based score for the prediction of bleeding in a contemporary cohort of patients receiving oral anticoagulation for venous thromboembolism.		
79	Bleeding Risk of Direct Oral Anticoagulants in Patients With Heart Failure And Atrial Fibrillation. 2021 , 14, e007230		3
78	Predicting major bleeding among hospitalized patients using oral anticoagulants for atrial fibrillation after discharge. <i>PLoS ONE</i> , 2021 , 16, e0246691	3-7	3
77	Real-world effectiveness and safety of rivaroxaban versus warfarin among non-valvular atrial fibrillation patients with obesity in a US population. <i>Current Medical Research and Opinion</i> , 2021 , 37, 881-890	2-5	5
76	Use of Non-Vitamin K Antagonist Oral Anticoagulants Among Patients with Nonvalvular Atrial Fibrillation and Multimorbidity. 2021 , 38, 3166-3184		2
75	Impact of oral anticoagulant choice for the secondary prevention of venous thromboembolism on the risk of inpatient bleeding. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021 , 5, e12514	5-1	0
74	Comparative Effectiveness and Safety of Rivaroxaban and Warfarin Among Nonvalvular Atrial Fibrillation (NVAf) Patients with Obesity and Polypharmacy in the United States (US). 2021 , 38, 3771-3788		1
73	Comparative effectiveness and safety of prasugrel versus ticagrelor following percutaneous coronary intervention: An observational study. 2021 , 41, 515-525		
72	Using a Simple Prescription Gap to Determine Warfarin Discontinuation Can Lead to Substantial Misclassification. <i>Thrombosis and Haemostasis</i> , 2021 ,	7	1
71	Clinical and Economic Outcomes Among Nonvalvular Atrial Fibrillation Patients With Coronary Artery Disease and/or Peripheral Artery Disease. 2021 , 148, 69-77		2
70	Characteristics, risk factors and outcomes of gastrointestinal hemorrhage in COVID-19 patients: A meta-analysis. 2021 , 37, 1524-1531		2
69	Dose specific effectiveness and safety of DOACs in patients with non-valvular atrial fibrillation: A Canadian retrospective cohort study. <i>Thrombosis Research</i> , 2021 , 203, 121-130	8.2	2
68	Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Valvular Atrial Fibrillation : A Population-Based Cohort Study. <i>Annals of Internal Medicine</i> , 2021 , 174, 910-919	8	8
67	Oral Anticoagulants for Nonvalvular Atrial Fibrillation in Patients With High Risk of Gastrointestinal Bleeding. 2021 , 4, e2120064		5
66	Effectiveness and safety of rivaroxaban versus warfarin among nonvalvular atrial fibrillation patients with obesity and diabetes. 2021 , 35, 108029		2
65	The Role of Direct Oral Anticoagulants in Cancer-Associated Thrombosis According to the Current Literature. 2021 , 57,		

64	Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients With Active Cancer. 2021 , 3, 411-424		3
63	Incidence of ischaemic stroke and mortality in patients with acute coronary syndrome and first-time detected atrial fibrillation: a nationwide study. 2021 , 42, 4553-4561		5
62	Frailty and Clinical Outcomes of Direct Oral Anticoagulants Versus Warfarin in Older Adults With Atrial Fibrillation : A Cohort Study. <i>Annals of Internal Medicine</i> , 2021 , 174, 1214-1223	8	11
61	Claims-Based Score for the Prediction of Bleeding in a Contemporary Cohort of Patients Receiving Oral Anticoagulation for Venous Thromboembolism. <i>Journal of the American Heart Association</i> , 2021 , 10, e021227	6	0
60	The Association between Factor XI Deficiency and the Risk of Bleeding, Cardiovascular, and Venous Thromboembolic Events. <i>Thrombosis and Haemostasis</i> , 2021 ,	7	3
59	Cardiovascular and major bleeding outcomes with antiplatelet and direct oral anticoagulants in patients with acute coronary syndrome and atrial fibrillation: A population-based analysis. <i>American Heart Journal</i> , 2021 , 242, 71-81	4.9	
58	Risk of Stroke and Bleeding in Atrial Fibrillation Treated with Apixaban Compared with Warfarin. <i>Journal of General Internal Medicine</i> , 2020 , 35, 3597-3604	4	2
57	Temporal trends in outpatient management of incident pulmonary embolism and associated mortality. <i>Thrombosis Research</i> , 2018 , 161, 111-116	8.2	14
56	Polypharmacy, Adverse Outcomes, and Treatment Effectiveness in Patients ≥65 With Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2020 , 9, e015089	6	8
55	Can We Predict Individual Combined Benefit and Harm of Therapy? Warfarin Therapy for Atrial Fibrillation as a Test Case. <i>PLoS ONE</i> , 2016 , 11, e0160713	3.7	3
54	Benefit of early discharge among patients with low-risk pulmonary embolism. <i>PLoS ONE</i> , 2017 , 12, e0185022	3.7	9
53	Apixaban 5 and 2.5 mg twice-daily versus warfarin for stroke prevention in nonvalvular atrial fibrillation patients: Comparative effectiveness and safety evaluated using a propensity-score-matched approach. <i>PLoS ONE</i> , 2018 , 13, e0191722	3.7	27
52	Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Diabetes. <i>Diabetes Therapy</i> , 2021 , 12, 3167-3186	3.6	1
51	Direct Oral Anticoagulants and Warfarin for Atrial Fibrillation Treatment: Rural and Urban Trends in Medicare Beneficiaries. <i>American Journal of Cardiovascular Drugs</i> , 2021 , 1	4	1
50	Inpatient Versus Outpatient Acute Venous Thromboembolism Management: Trends and Postacute Healthcare Utilization From 2011 to 2018. <i>Journal of the American Heart Association</i> , 2021 , 10, e020428	6	1
49	Non-persistence to Oral Anticoagulation Treatment in Patients with Non-valvular Atrial Fibrillation in the USA. <i>American Journal of Cardiovascular Drugs</i> , 2021 , 1	4	2
48	Incidence and characteristics of major bleeding among rivaroxaban users with renal disease and nonvalvular atrial fibrillation. <i>Clinical and Experimental Emergency Medicine</i> , 2018 , 5, 43-50	1.7	
47	Bleeding in cardiac patients prescribed antithrombotic drugs: Electronic health record phenotyping algorithms, incidence, trends and prognosis.		0

46	Incidence and risk factors of pulmonary hypertension after venous thromboembolism: An analysis of a large healthcare database.		
45	Economic Implications of Preventing Major Cardiovascular and Limb Events with Rivaroxaban plus Aspirin in Patients with Coronary or Peripheral Artery Disease in the United States. <i>American Health and Drug Benefits</i> , 2020 , 13, 184-190	1.7	
44	Real-World Anticoagulant Use and Incidence of Venous Thromboembolism and Major Bleeding in Children. <i>Clinical Therapeutics</i> , 2021 ,	3.5	2
43	Gender Related Differences in Gastrointestinal Bleeding With Oral Anticoagulation in Atrial Fibrillation.. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2022 , 27, 10742484211054609	2.6	1
42	Risk for Recurrent Venous Thromboembolism and Bleeding With Apixaban Compared With Rivaroxaban: An Analysis of Real-World Data. <i>Annals of Internal Medicine</i> , 2021 ,	8	7
41	Effectiveness and Safety of Rivaroxaban versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Polypharmacy.. <i>American Journal of Cardiovascular Drugs</i> , 2022 , 1	4	1
40	Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation.. <i>JAMA - Journal of the American Medical Association</i> , 2021 , 326, 2395-2404	27.4	14
39	Contemporary clinical and economic outcomes among oral anticoagulant treated and untreated elderly patients with atrial fibrillation: Insights from the United States Medicare database.. <i>PLoS ONE</i> , 2022 , 17, e0263903	3.7	
38	Long-term functional outcomes and mortality after hospitalization for extracranial hemorrhage.. <i>Journal of Hospital Medicine</i> , 2022 , 17, 235-242	2.7	
37	Hemodialysis Vascular Access and Risk of Major Bleeding, Thrombosis, and Cardiovascular Events: A Cohort Study. <i>Kidney Medicine</i> , 2022 , 100456	2.8	0
36	Association of Type of Oral Anticoagulant Dispensed With Adverse Clinical Outcomes in Patients Extending Anticoagulation Therapy Beyond 90 Days After Hospitalization for Venous Thromboembolism.. <i>JAMA - Journal of the American Medical Association</i> , 2022 , 327, 1051-1060	27.4	1
35	Worsening of kidney function in patients with atrial fibrillation and chronic kidney disease: evidence from the real-world CALLIPER study.. <i>Current Medical Research and Opinion</i> , 2022 , 1-31	2.5	1
34	Effectiveness and Safety of Apixaban versus Warfarin in Venous Thromboembolism Patients with Chronic Kidney Disease.. <i>Thrombosis and Haemostasis</i> , 2021 ,	7	4
33	Sex differences in treatment strategy and adverse outcomes among patients 75 and older with atrial fibrillation in the MarketScan database.. <i>BMC Cardiovascular Disorders</i> , 2021 , 21, 598	2.3	0
32	Bleeding outcomes of inpatients receiving therapeutic plasma exchange: A propensity-matched analysis of the National Inpatient Sample.. <i>Transfusion</i> , 2021 ,	2.9	
31	Effectiveness and safety of extended oral anticoagulant therapy in patients with venous thromboembolism: a retrospective cohort study.. <i>Clinical Pharmacology and Therapeutics</i> , 2022 ,	6.1	1
30	Apixaban Dosing Patterns Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation Receiving Dialysis: A Retrospective Cohort Study.. <i>American Journal of Kidney Diseases</i> , 2022 ,	7.4	1
29	Apixaban versus Warfarin for Treatment of Venous Thromboembolism in Patients Receiving Long-Term Dialysis.. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022 ,	6.9	0

28	An antiplatelet response gene expression signature is associated with bleeding.. <i>Cardiovascular Research</i> , 2022 ,	9.9	0
27	Effectiveness, safety, and healthcare costs associated with rivaroxaban versus warfarin among venous thromboembolism patients with obesity: a real-world study in the United States.. <i>Journal of Thrombosis and Thrombolysis</i> , 2022 , 1	5.1	1
26	Effectiveness and safety of oral anticoagulants in non-valvular atrial fibrillation patients with prior bleeding events: a retrospective analysis of administrative claims databases.. <i>Journal of Thrombosis and Thrombolysis</i> , 2022 ,	5.1	2
25	Cancer-associated venous thromboembolism in Israel: Incidence, risk factors, treatment, and health care utilization in a population based cohort study. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022 , 6,	5.1	
24	Rate of major bleeding with ibrutinib versus bendamustine-rituximab in chronic lymphocytic leukemia: a population-based cohort study. <i>American Journal of Hematology</i> ,	7.1	0
23	Incidence and Risk Factors of Pulmonary Hypertension After Venous Thromboembolism: An Analysis of a Large Health Care Database. <i>Journal of the American Heart Association</i> ,	6	0
22	Risk factors for recurrent venous thromboembolism: a real-world analysis. <i>Blood Coagulation and Fibrinolysis</i> , Publish Ahead of Print,	1	0
21	Comparative Safety of Sleeve Gastrectomy and Roux-en-Y: A Propensity Score Analysis. <i>World Journal of Surgery</i> ,	3.3	1
20	Impact of apixaban treatment discontinuation on the risk of hospitalization among patients with nonvalvular atrial fibrillation and COVID-19. 1-19		
19	Safety and effectiveness of apixaban versus warfarin for acute venous thromboembolism in patients with end-stage kidney disease: A national cohort study.		0
18	Comparative Effectiveness and Safety of Extended Anticoagulant Therapy among Medicare Beneficiaries with Venous Thromboembolism.		0
17	Putting external validation performance of major bleeding risk models into context. 2,		0
16	A RIVA-DM Subanalysis Investigating Patients With Nonvalvular Atrial Fibrillation and Type 2 Diabetes Aged Under Versus Over 80 Years. 2022 , 28, 107602962211330		0
15	International, Large-Scale, Real-World Clinical Data Confirm the Safety Profile of Rivaroxaban. 82-88		0
14	Comparative Effectiveness of Ticagrelor, Prasugrel, and Clopidogrel for Secondary Prophylaxis in Acute Coronary Syndrome: A Propensity Score-Matched Cohort Study.		0
13	Prescribing Patterns of Direct-Acting Oral Anticoagulants in Patients With Atrial Fibrillation and Chronic Kidney Disease: A Retrospective Cohort Analysis. 2022 , 27, 107424842211422		0
12	Comparative Risk of Hospitalized Bleeding of P2Y12 Inhibitors for Secondary Prophylaxis in Acute Coronary Syndrome after Percutaneous Coronary Intervention.		0
11	Bleeding with concomitant ibrutinib and oral anticoagulant therapy: A population-based cohort study.		0

- 10 Using Machine Learning to Develop a Clinical Prediction Model for SSRI-associated bleeding: a feasibility study. ○
- 9 Bleeding risk in patients with multiple myeloma treated for venous thromboembolism: a MarketScan analysis. **2023**, 7, 100024 ○
- 8 Effectiveness and Safety of Rivaroxaban Versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Concomitant Obstructive Sleep Apnea. ○
- 7 The relative risk of bleeding after medical hospitalization: the \square medical inpatient thrombosis and hemorrhage study. **2023**, 21, 513-521 ○
- 6 Effectiveness and Safety of Rivaroxaban \square and Low Molecular Weight Heparin in Cancer-Associated Venous \square Thromboembolism. **2023**, 5, 189-200 ○
- 5 Comparative Effectiveness and Safety of Direct Oral Anticoagulants and Warfarin in Patients With Atrial Fibrillation and Chronic Liver Disease: A Nationwide Cohort Study. **2023**, 147, 782-794 1
- 4 Comparative effectiveness and safety of direct oral anticoagulants versus warfarin among patients with recurrent venous thromboembolism. ○
- 3 Comparative Effectiveness and Safety of Oral Anticoagulants by Dementia Status in Older Patients With Atrial Fibrillation. **2023**, 6, e234086 ○
- 2 Trajectories of Oral Anticoagulation Adherence and Associated Clinical Outcomes During Long-Term Anticoagulation Among Medicare Beneficiaries With Venous Thromboembolism. 106002802311554 ○
- 1 Assessing the Clinical Treatment Dynamics of Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention in the US. **2023**, 6, e238585 ○